Amanda Letícia Polli Silvestre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amanda Letícia Polli Silvestre has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Marlus Chorilli
São Paulo State University (UNESP)
3 shared publications - Jonatas Lobato Duarte
School of Pharmaceutical Sciences, São Paulo State University “Julio de Mesquita Filho”—(UNESP), Araraquara 14800-903, SP, Brazil
2 shared publications - Leonardo Delello Di Filippo
São Paulo State University (UNESP)
2 shared publications - Alberto Gomes Tavares Junior
School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-901, SP, Brazil
1 shared publication - Bolívar Ponciano Goulart de Lima Damasceno
Universidade Estadual da Paraiba
1 shared publication - Bruna Almeida Furquim de Camargo
Department of Drugs and Medicines
1 shared publication
Latest Publications
- 1 April 2023
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 30 (12) , 1351-1367
Polymeric Systems for Colon-specific Mesalazine Delivery in the Intestinal Bowel Diseases Management
The anti-inflammatory 5-aminosalicylic acid (5-ASA) is the main therapeutic option used in the prevention and treatment of inflammatory bowel diseases. The upper intestinal tract performs rapid and almost complete absorption of this drug when administered orally., making local therapeutic levels of the molecule in the inflamed colonic mucosa difficult to achieve. Micro and nanoparticle systems are promising for 5-ASA incorporation because the reduced dimensions of these structures can improve the drug's pharmacodynamics and contribute to more efficient and localized therapy. Together, the association of these systems with polymers will allow the release of 5-ASA through specific targeting mechanisms to the colon, as demonstrated in mesalazine modified-release dosage form. In this review, the challenges for the oral administration of 5-ASA and the different colon-specific delivery strategies using polymers will be summarized and discussed.
- 1 April 2023
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 30 (12) , 1351-1367
Polymeric Systems for Colon-specific Mesalazine Delivery in the Intestinal Bowel Diseases Management
The anti-inflammatory 5-aminosalicylic acid (5-ASA) is the main therapeutic option used in the prevention and treatment of inflammatory bowel diseases. The upper intestinal tract performs rapid and almost complete absorption of this drug when administered orally., making local therapeutic levels of the molecule in the inflamed colonic mucosa difficult to achieve. Micro and nanoparticle systems are promising for 5-ASA incorporation because the reduced dimensions of these structures can improve the drug's pharmacodynamics and contribute to more efficient and localized therapy. Together, the association of these systems with polymers will allow the release of 5-ASA through specific targeting mechanisms to the colon, as demonstrated in mesalazine modified-release dosage form. In this review, the challenges for the oral administration of 5-ASA and the different colon-specific delivery strategies using polymers will be summarized and discussed.
- 28 May 2022
- Published by Taylor & Francis in Critical Reviews in Microbiology
- Vol. 49 (2) , 214-230
Functionalized lipid-based drug delivery nanosystems for the treatment of human infectious diseases
Infectious diseases are still public health problems. Microorganisms such as fungi, bacteria, viruses, and parasites are the main causing agents related to these diseases. In this context, the search for new effective strategies in prevention and/or treatment is considered essential, since current drugs often have side effects or end up, causing microbial resistance, making it a serious health problem. As an alternative to these limitations, nanotechnology has been widely used. The use of lipid-based drug delivery nanosystems (DDNs) has some advantages, such as biocompatibility, low toxicity, controlled release, the ability to carry both hydrophilic and lipophilic drugs, in addition to be easel scalable. Besides, as an improvement, studies involving the conjugation of signalling molecules on the surfaces of these nanocarriers can allow the target of certain tissues or cells. Thus, this review summarizes the performance of functionalized lipid-based DDNs for the treatment of infectious diseases caused by viruses, including SARS-CoV-2, bacteria, fungi, and parasites.
- 28 May 2022
- Published by Taylor & Francis in Critical Reviews in Microbiology
- Vol. 49 (2) , 214-230
Functionalized lipid-based drug delivery nanosystems for the treatment of human infectious diseases
Infectious diseases are still public health problems. Microorganisms such as fungi, bacteria, viruses, and parasites are the main causing agents related to these diseases. In this context, the search for new effective strategies in prevention and/or treatment is considered essential, since current drugs often have side effects or end up, causing microbial resistance, making it a serious health problem. As an alternative to these limitations, nanotechnology has been widely used. The use of lipid-based drug delivery nanosystems (DDNs) has some advantages, such as biocompatibility, low toxicity, controlled release, the ability to carry both hydrophilic and lipophilic drugs, in addition to be easel scalable. Besides, as an improvement, studies involving the conjugation of signalling molecules on the surfaces of these nanocarriers can allow the target of certain tissues or cells. Thus, this review summarizes the performance of functionalized lipid-based DDNs for the treatment of infectious diseases caused by viruses, including SARS-CoV-2, bacteria, fungi, and parasites.
- 30 December 2020
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (2) , 401-418
Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment
Monoclonal antibodies carried in nanosystems have been extensively studied and reported as a promising tool for the treatment of various types of cancers. Monoclonal antibodies have great advantages for the treatment of cancer because their protein structure can bind to the target tissue; however, it has some challenges such as denaturation following heat exposure and extreme values of pH, temperature and solvents, the ability to undergo hydrolysis, oxidation and deamination and the formation of non-native aggregates, which compromise drug stability to a large extent. In addition to these characteristics, they suffer rapid elimination when in the blood, which results in a short half-life and the production of neutralizing antibodies, rendering the doses ineffective. These challenges are overcome with encapsulation in nanosystems (liposomes, polymer nanoparticles, cyclodextrins, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers and micelles) due to the characteristics of improving solubility, permeability, and selectivity only with tumor tissue; with that, there is a decrease in side effects beyond controlled release, which is critical to improving the therapeutic efficacy of cancer treatment. The article was divided into different types of nanosystems, with a description of their definitions and applications in various types of cancers. Therefore, this review summarizes the use of monoclonal antibodies encapsulated in nanosystems and the description of clinical studies with biosimilars. Biosimilars are defined as products that are similar to monoclonal antibodies which are produced when the patent for the monoclonal antibodies expires.
- 30 December 2020
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (2) , 401-418
Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment
Monoclonal antibodies carried in nanosystems have been extensively studied and reported as a promising tool for the treatment of various types of cancers. Monoclonal antibodies have great advantages for the treatment of cancer because their protein structure can bind to the target tissue; however, it has some challenges such as denaturation following heat exposure and extreme values of pH, temperature and solvents, the ability to undergo hydrolysis, oxidation and deamination and the formation of non-native aggregates, which compromise drug stability to a large extent. In addition to these characteristics, they suffer rapid elimination when in the blood, which results in a short half-life and the production of neutralizing antibodies, rendering the doses ineffective. These challenges are overcome with encapsulation in nanosystems (liposomes, polymer nanoparticles, cyclodextrins, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers and micelles) due to the characteristics of improving solubility, permeability, and selectivity only with tumor tissue; with that, there is a decrease in side effects beyond controlled release, which is critical to improving the therapeutic efficacy of cancer treatment. The article was divided into different types of nanosystems, with a description of their definitions and applications in various types of cancers. Therefore, this review summarizes the use of monoclonal antibodies encapsulated in nanosystems and the description of clinical studies with biosimilars. Biosimilars are defined as products that are similar to monoclonal antibodies which are produced when the patent for the monoclonal antibodies expires.